EBV Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about EBV clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 1

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

EBV Infection After Allogenic HSCT
Chinese PLA General Hospital12 enrolled1 locationNCT06119256
Recruiting

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

HPVHSVEBV+2 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT01011712
Recruiting
Phase 1

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)750 enrolled1 locationNCT06908096
Recruiting
Not Applicable

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

EBV-associated T/NK-cell Lymphoproliferative DiseasesRefractory/Relapsed EBV-related Hemophagocytic LymphohistiocytosisLetermovir
Beijing Children's Hospital80 enrolled1 locationNCT07488728
Recruiting
Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Phase 1

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+3 more
University of Washington56 enrolled1 locationNCT04231877
Recruiting
Phase 1Phase 2

EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

Epstein-Barr Virus-Associated Lymphoproliferative DisordersEBV-Positive Lymphoma
Daihong Liu18 enrolled1 locationNCT07450391
Recruiting
Phase 1Phase 2

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEBV-DNA Viremia
Daihong Liu18 enrolled1 locationNCT07438067
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2

Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders

Epstein-Barr Virus-associated Lymphoproliferative DiseasesChronic Active Epstein-Barr Virus InfectionEBV Associated Lymphoma+1 more
Fudan University80 enrolled2 locationsNCT07381738
Recruiting
Phase 2

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373
Recruiting
Phase 2Phase 3

Golidocitinib Combined With Selinexor for CAEBVD

EBVLymphohistiocytosisCAEBV
Beijing Friendship Hospital28 enrolled1 locationNCT07369739
Recruiting
Phase 1Phase 2

GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms

EBV Associated Lymphoid Neoplasms
Zhimin Zhai24 enrolled1 locationNCT07306156
Recruiting
Phase 1

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

EBV-Related Hodgkin LymphomaEBV-Related Lymphoproliferative DisorderEBV Related Non-Hodgkin's Lymphoma
Baylor College of Medicine52 enrolled2 locationsNCT04664179
Recruiting
Not Applicable

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Kidney Transplantation, Cytomegalovirus InfectionsEBV InfectionAntiviral Prophylaxis
National Taiwan University Hospital80 enrolled1 locationNCT07294547
Recruiting
Phase 1

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection
Thomas Jefferson University30 enrolled1 locationNCT06789159
Recruiting

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Autoimmune HepatitisSystemic Lupus ErythematosusHemophagocytic Lymphohistiocytoses+17 more
Institut National de la Santé Et de la Recherche Médicale, France500 enrolled1 locationNCT04902807
Recruiting
Phase 1

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more
Timothy Voorhees26 enrolled2 locationsNCT06672705
Recruiting
Phase 3

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Stem Cell Transplant ComplicationsEBV InfectionCMV Infection+1 more
Tobias Feuchtinger149 enrolled33 locationsNCT04832607